NASDAQ:DWTX Dogwood Therapeutics Q2 2026 Earnings Report $2.32 -0.34 (-12.78%) Closing price 04:00 PM EasternExtended Trading$2.36 +0.04 (+1.72%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Dogwood Therapeutics EPS ResultsActual EPS-$0.34Consensus EPS -$0.14Beat/MissMissed by -$0.20One Year Ago EPSN/ADogwood Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADogwood Therapeutics Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time8:30AM ETUpcoming EarningsDogwood Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Dogwood Therapeutics Earnings HeadlinesHC Wainwright Has Bearish Forecast for DWTX Q3 EarningsAugust 20, 2026 | americanbankingnews.comDogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026August 17, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.August 27 at 1:00 AM | Porter & Company (Ad)What is HC Wainwright's Estimate for DWTX FY2029 Earnings?August 17, 2026 | americanbankingnews.comDogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Second Quarter 2026 Financial ResultsAugust 13, 2026 | finanznachrichten.deDogwood Therapeutics Announces Second Quarter 2026 Financial ResultsAugust 13, 2026 | globenewswire.comSee More Dogwood Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email. Email Address About Dogwood TherapeuticsDogwood Therapeutics (NASDAQ:DWTX) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential. Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients. Its preclinical pipeline includes antibody and protein candidates targeting key inflammatory and fibrotic pathways. In addition to cardiovascular indications, the company is evaluating opportunities in liver and renal fibrosis, with plans to advance multiple programs into IND‐enabling studies over the coming year. Founded in 2021 and headquartered in Vancouver, British Columbia, Dogwood Therapeutics also maintains research operations in Boston, Massachusetts. The company works in collaboration with academic institutions and clinical research organizations across North America to support its development efforts. Led by an experienced management team with backgrounds in biologics discovery and cardiovascular drug development, Dogwood is positioning itself to address significant unmet needs in fibrotic disease.View Dogwood Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes ShapeNVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout IsMarvell’s Big AI Test Comes One Day After NVIDIA’s Blowout QuarterWhen Unusual Volume Isn't Noise: 3 Small-Caps Sending SignalsSemtech Stock Rallies on Strong Q2 Results and Raised GuidanceWilliams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-RaiseSEC Probe Puts Wall Street Leverage Risk Back in Focus Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
